Investors

Innate Pharma S.A is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

23-Sep-21

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021

Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities ( Autorité des Marchés Financiers , or “ AMF ”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)

17-Sep-21

Monalizumab Data From COAST Trial Presented at ESMO Congress 2021

Marseille, France , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical

15-Sep-21

Innate Pharma reports first half 2021 financial results and business update

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) -- First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre-clinical data presented from next-generation NK cell